OBJECTIVE: To prepare and evaluate the quality of clarithromycin microcapsules.METHODS: Clarithromycin microcapsules were prepared by emulsion-solvent volatilixation method using ethylcellulose as capsule wall material.The particle size,entrapment efficiency,the loading amount and the drug release property in vitro were investigated.RESULTS: The prepared microcapsules were well-distributed in particle size with average particle size at 33.0～38.0 ?m,encapsulation efficiency at above 87%,loading amount above 45%,and accumulative drug release rate of 75% at 6 h.CONCLUSION: The method is simple and feasible and the quality of prepared microcapsules is up to the standard.

OBJECTIVE:To prepare epirubicin hydrochloride solid lipid nanoparticle(EPI-SLN) and investigate its physicochemical property. METHODS: EPI-SLN was prepared by ultrasonic dispersion technique with glyceryl behenate as matrix,and the appearance,particle size,? electric potential,and entrapment efficiency of the SLN were evaluated and its stability at 3 month storing at 4 ℃ was investigated. RESULTS: EPI-SLN assumed spherical shape with a particle diameter of (212.8?6.2) nm,? electric potential of (-24.7?0.3) mV and entrapment efficiency of 82 %. The EPI-SLN at 4 ℃ was stable after storing for 3 months,showing no marked change in mean diameter,? electric potential or entrapment efficiency. CONCLUSION: The prepared EPI-SLN is up to the standard.

In order to select better seeding sludge and promote start-up of Anammox reactors, we studied the start-up performances of three Anammox-EGSB bioreactors inoculated with anaerobic methanogenic sludge (AMS) (R1), Fresh Anammox sludge (FAS) (R2) and stored Anammox sludge (SAS) (R3), respectively. Results showed that these three seeding sludges could start up Anammox-EGSB bioreactors successfully, but the start-up progresses showed different characteristics. The start-up course of R1 could be divided into three phases including autolysis phase (15 d), lag phase (54 d) and activity elevation phase (40 d). However, the start-up courses of R2 and R3 only included lag phase (2 d and 12 d, respectively) and activity elevation phase (15 d and 57 d, respectively). Besides, the performance of R3 was better than that of R1, but worse than that of R2. Furthermore, bathing the Anammox sludge in the effluent of bioreactors was a convenient and effective way to keep the activity of the Anammox sludge. The ammonia removal efficiency, percentage of denitrification and the stoichiometric ratios of NH4(+)-Nr/NO2(-)-Nr and NO3(-)-Np/NH4(+)-Nr could serve as indicators to monitor the start-up of Anammox bioreactors.
Bacteria, Anaerobic ; metabolism ; Biodegradation, Environmental ; Bioreactors ; microbiology ; Nitrogen ; metabolism ; Oxidation-Reduction ; Quaternary Ammonium Compounds ; metabolism ; Sewage ; chemistry ; Water Pollutants, Chemical ; metabolism

OBJECTIVETo study the water-soluble non-alkaloid chemical constituents of Corydalis yanhusuo.

METHODThe 80% alcohol extracts of C. yanhusuo passed through DA201 macroporous resin. Eluted fractions were collected and passed though 732 # cation exchange resin. Water eluate was collected, dried and derived with trimethylsilane. Gas Chromatography/Mass Spectrometry and NIST 2005 library were adopted for MS/MS mass spectrogram to infer the compound structure.

RESULTSixteen compounds were tentatively identified from about fifty peaks detected by GC-MS and identified as hydroxyl and carboxyl polar compounds.

CONCLUSIONThese sixteen compounds were found for the first time in C. yanhusuo. The results provide scientific basis for in-depth development of C. yanhusuo.

Corydalis ; chemistry ; Gas Chromatography-Mass Spectrometry ; methods ; Solubility ; Trimethylsilyl Compounds ; chemistry

OBJECTIVETo evaluate the treatment for patients with major vascular injuries associated with traumatic orthopedic injuries.

METHODSA total of 196 patients, aged from 4-67 years with the mean age of 29.88 years, had major vascular injuries associated with traumatic orthopedic injuries and were treated in our hospital in a period of 44 years. The most common mechanism of trauma was blunt trauma (67.3%), open injuries accounted for 32.4% and 54.5% of the injuries were located in the lower extremities. The vascular injury frequently happened in the femoral artery (26.7%) and popliteal artery (20.3%). The treatment principle consisted of aggressive resuscitation, Doppler imaging and stable bone internal fixation with subsequent vascular repair and debridement. The vascular repair for injuries included end-to-end anastomosis (80 cases, 39.6%), interpositional vein graft (94, 46.5%), vascular decompression through fracture distraction (18, 8.9%), arterial ligation (6, 3.0%), vein patch (2, 1.0%), bypass graft (2, 1.0%), venous repair including autogenous vein graft (9, 24.3%) and ligation (28, 75.7%) and prophylactical fasciotomy (15, 7.4%). Postoperative amputation was performed in 16 cases (16.3%).

RESULTSNo intraoperative death was observed and all fractures united within 6 months. Limbs were salvaged in 180 patients (91.8%). Among these patients, early complications were found in 19 patients (9.7%) and late complications were observed in 8 patients (4.1%).

CONCLUSIONSA well-organized approach, based on a specific treatment principle, not only improves clinical outcome but also does good to excellent functional recovery for patients with severe orthopedic injuries and concomitant vascular lesion.

Adolescent ; Adult ; Blood Vessels ; injuries ; Child ; Child, Preschool ; Female ; Fracture Fixation, Internal ; Fractures, Bone ; complications ; Fractures, Open ; complications ; Humans ; Male ; Middle Aged ; Prospective Studies

Objective: To explore the inhibitory effect of icotinib combined with cytokine induced killer (CIK) on various human lung adenocarcinoma cell lines in vitro. Methods: The inhibitory effect of icotinib alone or icotinib combined with CIK on HCC827 and A549 cells was detected by cell counting kit-8(CCK-8). The apoptosis was detected by flow cytometry via Annexin V/PI staining. The effect of icotinib on CIK phenotype was detected by flow cytometry. Results: The inhibitory rates of HCC827 cells treated with 1.5, 3, 6, 12 μmol/L icotinib were (5.64±0.05)%, (8.62±0.45)%, (14.57±0.65)% and (18.52±0.91)%, respectively. The inhibitory rates of A549 cells were (1.64±0.48)%, (2.09±0.28)%, (3.69±0.45)%, (4.41±0.58)%, respectively. At the same concentration, the inhibitory rate of HCC827 cells with icotinib treatment was significantly higher than that of A549 cells (P<0.05). When the effector/target ratio was 10∶1, 20∶1 or 40∶1, the inhibitory rates of HCC827 cells co-cultured with CIK were (15.17±2.33)%, (42.59±7.18)%, (62.59±8.95)%, respectively, and the inhibitory rates of A549 were(16.99±2.81)%, (46.31±1.89)%, (58.24±4.23)%, respectively. The inhibitory rate of HCC827 cells co-cultured with CIK was not significantly different from that of A549 cells at the same effector/target ratio (P_10∶1=0.299, P_20∶1=0.318, P_40∶1=0.366). When the effector/target ratio of CIK combined with 6 μmol/L icotinib was 10∶1, 20∶1 or 40∶1, the inhibitory rates of HCC827 cells were (37.07±3.50)%, (76.03±6.55)%, (80.34±10.69)%, respectively, and the inhibitory rates of A549 cells were(25.72±1.41)%, (52.76±3.82)%, (62.26±1.94)%, respectively. The inhibitory rates of 6 μmol/L icotinib combined with CIK were significantly higher than those of icotinib group and CIK group alone at the same effector/target ratio (P<0.05), except for the effector/target ratio at 40︰1 on A549 cells (P=0.089). Moreover, all of the combination index (CI) of combined group were <1 (P<0.05). The apoptotic rates of HCC827 and A549 cells induced by icotinib combined with CIK were significantly higher than those of icotinib group and blank control group (P<0.05), especially the proportion of late apoptotic or necrotic cells.Increasing effector/target ratio of CIK contributed to stronger inhibition(P<0.05). The expressional rate of CIK phenotype with or without icotinib treatment was not significantly different from each other(P>0.05). Conclusions EGFR mutant lung adenocarcinoma cells are more sensitive to icotinib, while the EGFR mutation status has no effect on the killing effect of CIK cells. icotinib combined with CIK has a synergistic effect on the inhibition of tumor growth, and icotinib has no any impact on the phenotype of CIK cells.